£1.5M
The pre-seed round was co-led by Kadmos Capital and Exceptional Ventures and will support the transition of designed drug combinations into wet-lab validation.
"Cancer is not one disease driven by one target, but we still develop drugs as if it were. Combinations are how we beat it – and with more than 900 billion of them possible, no lab on earth can test its way to the right ones. That is the problem we built Big Picture Bio to solve: model the disease as the dynamic system it actually is, then design against it – combinations chosen because they are most likely to work in patients, not because they were the ones we could get to. This funding takes our first designed combinations out of the model and into the lab."
